Current Report Filing (8-k)
20 April 2019 - 5:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 15, 2019
|
Applied BioSciences Corp.
|
|
(Exact name of registrant as specified in its charter)
|
Nevada
(State or other jurisdiction of incorporation)
000-55523
(Commission File Number)
81-1699502
(IRS Employer Identification No.)
9701 Wilshire Blvd., Suite 1000
Beverly Hills, California 90212
(Address of principal executive offices)(Zip Code)
(310) 356-7374
Registrant’s telephone number, including area code
________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 15, 2019, the board of directors of Applied BioSciences Corp., a Nevada corporation (the “Company”), appointed Scott Stevens, age 43, as a director of the Company. The board of directors of the Company is now comprised of three persons: Chris Bridges, John Brady and Scott Stevens.
Since 2014, Mr. Stevens has been a Partner at Grays Peak Capital, a global investment firm located in New York. Mr. Stevens has over twenty years of global investment experience in finance, technology, consulting and M&A. Prior to Grays Peak, Mr. Stevens was a Portfolio Manager for sixteen years in public and private market investing. Before joining the buyside, Mr. Stevens was an Analyst at Merrill Lynch & Co. in the Mergers & Acquisitions Group where he completed over $20 billion of transactions in various sectors including aerospace/defense, media, healthcare, and energy. Mr. Stevens graduated from the University of Michigan (BA Economics) in 1998. Mr. Stevens’ experience in finance and M&A led to our conclusion that Mr. Stevens should be serving as a member of our board of directors in light of our business and structure.
On April 15, 2019, we entered into an Indemnification Agreement, with Mr. Stevens, pursuant to which the Company agreed to indemnify Mr. Stevens for claims against him that may arise in connection with the performance of his duties as a director for the Company. Mr. Stevens does not have any other agreement, arrangement or understanding with the Company.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Applied BioSciences Corp.
|
|
|
|
|
|
|
Date: April 19, 2019
|
By:
|
/s/ Chris Bridges
|
|
|
|
Name:
|
Chris Bridges
|
|
|
|
Title:
|
President
|
|
Applied Biosciences (CE) (USOTC:APPB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Applied Biosciences (CE) (USOTC:APPB)
Historical Stock Chart
From Dec 2023 to Dec 2024
